Litcius/Paper detail

AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Léna Carmès, Guillaume Bort, François Lux, Léa Seban, Paul Rocchi, Zeinaf Muradova, Agnès Hagège, Laurence Heinrich-Balard, Frédéric Delolme, Virginie Gueguen‐Chaignon, Charles Truillet, Stephanie J. Crowley, Elisa Bello, Tristan Doussineau, Michael Dougan, Olivier Tillement, Jonathan D. Schoenfeld, Needa Brown, Ross Berbeco

2023Nanoscale11 citationsDOIOpen Access PDF

Abstract

Comparison of click chemistry and sortagging grafting strategies for functionalizing AGuIX nanoparticles with nanobodies to develop a tri-functional technology combining MRI imaging, radiotherapy, and immunotherapy by inhibiting immune checkpoints.

Topics & Concepts

BiodistributionBioconjugationChemistryIn vivoNanotechnologyEx vivoClick chemistryIn vitroBiophysicsComputational biologyCancer researchCombinatorial chemistryBiochemistryMaterials scienceBiologyBiotechnologyMonoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune ResponsesClick Chemistry and Applications
AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors | Litcius